Posted by Michael Wonder on 08 Oct 2023
Sun Pharma announces US FDA filing acceptance of new drug application for deuruxolitinib
6 October 2023 - Deuruxolitinib is being evaluated for treatment of moderate to severe alopecia areata.
Sun Pharmaceutical Industries today announced that the US FDA has accepted the new drug application for deuruxolitinib, an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adults with moderate to severe alopecia areata.
